Low-dose CT lung cancer screening in never-smokers and smokers: results of an eight-year observational study.

BACKGROUND: This was an observational study of Japanese participants who underwent low-dose computed tomographic (LDCT) lung cancer screening between February 2004 and March 2012, to evaluate the lung cancers in never-smokers and smokers. METHODS: The study population consisted of a total of 12,114 subjects [never-smokers, 6,021 (49.70%); smokers with <30 pack-years of smoking, 3,785 (31.24%); smokers with ≥30 pack-years of smoking, 2,305 (19.03%); unknown smoking status, 3 (0.02%)]. The odds ratio (OR) of lung cancer detection according to the smoking status adjusted for age and gender was evaluated. RESULTS: A total of 152 lung cancers were diagnosed in 133 patients [never-smokers, 66 (49.6%); smokers with <30 pack-years of smoking, 31 (23.3%); smokers with ≥30 pack-years of smoking, 36 (27.1%)]; therefore, 72.9% of lung cancer patients did not meet the National Lung Screening Trial (NLST) criterion of smokers with ≥30 pack-years of smoking. The OR of lung cancer detection in smokers with ≥30 pack-years of smoking was higher than that in the never-smokers (OR =1.71, 95% CI: 1.04-2.82, P=0.03) and that in smokers with <30 pack-years of smoking (OR =1.71, 95% CI: 1.04-2.80, P=0.03), while the OR of lung cancer detection in smokers with <30 pack-years of smoking was the same as that in the never-smokers (OR =1.00, 95% CI: 0.62-1.61, P=0.99). CONCLUSIONS: Although the OR of lung cancer detection in smokers with ≥30 pack-years of smoking was higher than that in the never-smokers and smokers with <30 pack-years of smoking, approximately 70% of lung cancer patients might be missed if we only adopted the NLST criterion of smokers with ≥30 pack-years of smoking. Therefore, never-smokers and smokers with <30 pack-years of smoking should be included in the target population for LDCT lung cancer screening in Japan.

Evaluation of the 95% limits of agreement of the volumes of 5-year clinically stable solid nodules for the development of a follow-up system for indeterminate solid nodules in CT lung cancer screening.

BACKGROUND: This study sought to evaluate the 95% limits of agreement of the volumes of 5-year clinically stable solid nodules for the development of a follow-up system for indeterminate solid nodules. METHODS: The volumes of 226 solid nodules that had been clinically stable for 5 years were measured in 186 patients (53 female never-smokers, 36 male never-smokers, 51 males with <30 pack-years, and 46 males with ≥30 pack-years) using a three-dimensional semiautomated method. Volume changes were evaluated using three methods: percent change, proportional change and growth rate. The 95% limits of agreement were evaluated using the Bland-Altman method. RESULTS: The 95% limits of agreement were as follows: range of percent change, from ±34.5% to ±37.8%; range of proportional change, from ±34.1% to ±36.8%; and range of growth rate, from ±39.2% to ±47.4%. Percent change-based, proportional change-based, and growth rate-based diagnoses of an increase or decrease in ten solid nodules were made at a mean of 302±402, 367±455, and 329±496 days, respectively, compared with a clinical diagnosis made at 809±616 days (P<0.05). CONCLUSIONS: The 95% limits of agreement for volume change in 5-year stable solid nodules may enable the detection of an increase or decrease in the solid nodule at an earlier stage than that enabled by a clinical diagnosis, possibly contributing to the development of a follow-up system for reducing the number of additional Computed tomography (CT) scans performed during the follow-up period.

Ultra-High-Resolution Computed Tomography of the Lung: Image Quality of a Prototype Scanner.

PURPOSE: The image noise and image quality of a prototype ultra-high-resolution computed tomography (U-HRCT) scanner was evaluated and compared with those of conventional high-resolution CT (C-HRCT) scanners. MATERIALS AND METHODS: This study was approved by the institutional review board. A U-HRCT scanner prototype with 0.25 mm x 4 rows and operating at 120 mAs was used. The C-HRCT images were obtained using a 0.5 mm x 16 or 0.5 mm x 64 detector-row CT scanner operating at 150 mAs. Images from both scanners were reconstructed at 0.1-mm intervals; the slice thickness was 0.25 mm for the U-HRCT scanner and 0.5 mm for the C-HRCT scanners. For both scanners, the display field of view was 80 mm. The image noise of each scanner was evaluated using a phantom. U-HRCT and C-HRCT images of 53 images selected from 37 lung nodules were then observed and graded using a 5-point score by 10 board-certified thoracic radiologists. The images were presented to the observers randomly and in a blinded manner. RESULTS: The image noise for U-HRCT (100.87 ± 0.51 Hounsfield units [HU]) was greater than that for C-HRCT (40.41 ± 0.52 HU; P < .0001). The image quality of U-HRCT was graded as superior to that of C-HRCT (P < .0001) for all of the following parameters that were examined: margins of subsolid and solid nodules, edges of solid components and pulmonary vessels in subsolid nodules, air bronchograms, pleural indentations, margins of pulmonary vessels, edges of bronchi, and interlobar fissures. CONCLUSION: Despite a larger image noise, the prototype U-HRCT scanner had a significantly better image quality than the C-HRCT scanners.

Solitary Pure Ground-Glass Nodules 5 mm or Smaller: Frequency of Growth.

PURPOSE: To clarify the percentage of solitary pure ground-glass nodules (SPGGNs) 5 mm or smaller that grow and develop into invasive adenocarcinomas. MATERIALS AND METHODS: This study was approved by the institutional review board, and informed consent was obtained from all people who were screened. From February 2004 through December 2007, 7294 participants underwent screening for lung cancer with computed tomographic (CT) imaging. The nodule database was reviewed to identify SPGGNs 5 mm or smaller. Growth of the SPGGNs was evaluated as of March 31, 2013. In cases of pathologic analysis-proven adenocarcinomas that developed from SPGGNs 5 mm or smaller, solid components were evaluated. Percentages, 95% confidence intervals, and means were calculated. RESULTS: At baseline screening, 438 SPGGNs 5 mm or smaller were identified, and during the study period one SPGGN 5 mm or smaller developed de novo. Of the 439 SPGGNs, 394 were stable and 45 (10.3% [95% confidence interval: 7.5%, 13.7%]), including newly developed SPGGN, grew. Of the 45 SPGGNs that grew, 0.9% (four of 439 [95% confidence interval: 0.3%, 2.3%]) developed into adenocarcinomas (two minimally invasive [including the newly developed SPGGN] and two invasive). The mean period between baseline CT screening and the appearance of solid components in the four adenocarcinomas was 3.6 years. CONCLUSION: Of SPGGNs 5 mm or smaller, approximately 10% will grow and 1% will develop into invasive adenocarcinomas or minimally invasive adenocarcinomas. SPGGNs 5 mm or smaller should be rescanned 3.5 years later to look for development of a solid component.

Usefulness of a glass-free medical three-dimensional autostereoscopic display in neurosurgery.

PURPOSE: Many stereoscopic displays require glasses that are awkward or inappropriate for use in a neurosurgical operating room. A glass-free three-dimensional autostereoscopic display (3DAD) monitor was developed and tested for neurosurgical applications. METHODS: Our 3DAD system uses images acquired from nine directions projected into the viewer's eyes through 1,280 lenticular lenses (1,280 x 720 pixels). The viewer interprets these as a single stereoscopic image. To evaluate the 3D visualization capabilities of the 3DAD system, 3D images of blood vessels created from brain magnetic resonance angiography were presented to 20 neurosurgeons on both a standard medical two-dimensional (2D) monitor and our 3DAD monitor. Discrimination of the positional relationships for each vessel was recorded. The observers were asked to identify blood vessels located in front of three pairs of points on each image. RESULTS: The neurosurgeon observers achieved significantly higher correct responses using the 3DAD monitor compared with the 2D monitor (91.7 vs. 56.7 %, p< 0.0001). There were no reports of problems such as eye fatigue or discomfort. CONCLUSION: Displaying 3D volume rendered multimodality images with a 3DAD monitor is useful for anatomical discrimination of 3D vessels in MR angiography. This technology may be useful for a wide variety of clinical applications such as rapid and precise diagnosis, surgical simulation, and medical education.

Fibrosis and postoperative fistula of the pancreas: correlation with MR imaging findings--preliminary results.

PURPOSE: To assess the potential value of magnetic resonance (MR) imaging in evaluating pancreatic fibrosis and predicting the development of postoperative pancreatic fistula. MATERIALS AND METHODS: This retrospective study had institutional review board approval, and the requirement for informed consent was waived. MR images obtained in 29 consecutive patients (15 men, 14 women; mean age, 64.9 years; age range, 21-80 years) who underwent pancreatectomy were evaluated. The pancreas-to-muscle signal intensity (SI) ratio on unenhanced T1- and T2-weighted, dynamic contrast material-enhanced, and diffusion-weighted images and the apparent diffusion coefficient (ADC) of the pancreas were measured. MR imaging parameters were correlated with the degrees of pancreatic fibrosis and expression of activated pancreatic stellate cells (PSCs) by using univariate and multivariate regression analyses and receiver operating characteristic curve analysis. The relationships between the development of postoperative pancreatic fistula and the MR imaging measurements were examined by using logistic regression analysis and the Mann-Whitney U test. RESULTS: Multiple regression analysis showed that pancreas-to-muscle SI ratios on T1-weighted images and ADC values were independently associated with pancreatic fibrosis (r(2) = 0.66, P < .001) and with activated PSC expression (r(2) = 0.67, P < .001). The mean pancreas-to-muscle SI ratio (± standard deviation) on T1-weighted images was higher (P = .0029) for patients with postoperative pancreatic fistula (1.6 ± 0.2) than for those without (1.2 ± 0.2), and the odds ratio for postoperative pancreatic fistula was 21.3 in patients with an SI ratio of 1.41 and higher. CONCLUSION: The pancreas-to-muscle SI ratio on T1-weighted MR images of the pancreas may be a potential biomarker for assessment of pancreatic fibrosis and prediction of postoperative pancreatic fistula.

Evaluation of a near-infrared-type contrast medium extravasation detection system using a swine model.

PURPOSE: To refine the development and evaluate the near-infrared (NIR) extravasation detection system and its ability to detect extravasation during a contrast-enhanced computed tomography (CT) examination. MATERIALS AND METHODS: The NIR extravasation detection system projects the NIR light through the surface of the human skin then, using its sensory system, will monitor the changes in the amount of NIR that reflected, which varies based on absorption properties.Seven female pigs were used to evaluate the contrast media extravasation detection system, using a 20-gauge intravenous catheter, when injected at a rate of 1 mL/s into 4 different locations just under the skin in the thigh section. Using 3-dimensional CT images, we evaluated the extravasations between time and volume, depth and volume, and finally depth and time to detect. RESULTS: We confirmed that the NIR light, 950-nm wavelength, used by the extravasation detection system is well absorbed by contrast media, making changes easy to detect. The average time to detect an extravasation was 2.05 seconds at a depth of 2.0 mm below the skin with a volume of 1.3 mL, 2.57 seconds at a depth between 2.1 and 5 mm below the skin and a volume of 3.47 mL, 10.5 seconds for depths greater than 5.1 mm and a volume of 11.1 mL. The detection accuracy was significantly deteriorated when the depth exceeded 5.0 mm (Tukey-Kramer, P < 0.05) CONCLUSIONS: The extravasation system detection system that is using NIR has a high level of detection sensitivity. The sensitivity enables the system to detect extravasation at depths less than 2 mm with a volume of 1.5 mL and at depths less than 5 mm with a volume of 3.5 mL. The extravasation detection system could be suitable for use during examinations.

Characterizing focal hepatic lesions by free-breathing intravoxel incoherent motion MRI at 3.0 T.

BACKGROUND: Diffusion-weighted (DW) imaging is commonly used to distinguish between benign and malignant liver lesions. PURPOSE: To prospectively evaluate the true molecular-diffusion coefficient (D), perfusion-related diffusion coefficient (D*), perfusion fraction (f), and ADC of focal hepatic lesions using a free-breathing intravoxel incoherent motion (IVIM) DW sequence, and to determine if these parameters are useful for characterizing focal hepatic lesions. MATERIAL AND METHODS: One hundred and twenty hepatic lesions (34 metastases, 32 hepatocellular carcinoma [HCC], 33 hemangiomas, and 21 liver cysts) in 74 patients were examined. Mean D, D*, f, and ADC values of hepatic lesions were compared among pathologies. ROC curve analyses were performed to assess the performances of D, D*, f, and ADC values for the characterization of liver lesions as benign or malignant. RESULTS: The mean D and ADC values of benign lesions were greater than those of malignant lesions (P < 0.001). Although the mean D and ADC values of liver cysts were greater than those of hemangiomas (P < 0.001), and these values were not significantly different between metastases and HCCs (P = 0.99). Area under the ROC curve for ADC values (0.98) was significantly greater (P = 0.048) than that for D values (0.96) for the differentiation of benign and malignant lesions. Sensitivity and specificity for the detection of malignant lesion were 89% and 98%, respectively, when an ADC cut-off value of 1.40 was applied. CONCLUSION: D and ADC values have more potential for characterizing focal hepatic lesions than D* or f values, and for the differentiation of malignancy and benignity.

Blood vessel-based liver segmentation using the portal phase of an abdominal CT dataset.

PURPOSE: Blood vessel (BV) information can be used to guide body organ segmentation on computed tomography (CT) imaging. The proposed method uses abdominal BVs (ABVs) to segment the liver through the portal phase of an abdominal CT dataset. This method aims to address the wide variability in liver shape and size, separate liver from other organs of similar intensity, and segment hepatic low-intensity tumors (LITs). METHODS: Thin ABVs are enhanced using three-dimensional (3D) opening. ABVs are extracted and classified into hepatic BVs (HBVs) and nonhepatic BVs (non-HBVs) with a small number of interactions, and HBVs and non-HBVs are used for constraining automatic liver segmentation. HBVs are used to individually segment the core region of the liver. To separate the liver from other organs, this core region and non-HBVs are used to construct an initial 3D boundary surface. To segment LITs, the core region is classified into non-LIT- and LIT-parts by fitting the histogram of the core region using a variational Bayesian Gaussian mixture model. Each part of the core region is extended based on its corresponding component of the mixture, and extension is completed when it reaches a variation in intensity or the constructed boundary surface, which is reconfirmed to fit robustly between the liver and neighboring organs of similar intensity. A solid-angle technique is used to refine main BVs at the entrances to the inferior vena cava and the portal vein. RESULTS: The proposed method was applied to 80 datasets: 30 Medical Image Computing and Computer Assisted Intervention (MICCAI) and 50 non-MICCAI; 30 datasets of non-MICCAI data include tumors. Our results for MICCAI-test data were evaluated by sliver07 (http://www.sliver07.org/) organizers with an overall score of 85.7, which ranks best on the site as of July 2013. These results (average ± standard deviation) include the five error measures of the 2007 MICCAI workshop for liver segmentation as follows. Results for volume overlap error, relative volume difference, average symmetric surface distance, root mean square symmetric surface distance, and maximum symmetric surface distance were 4.33 ± 0.73, 0.28 ± 0.87, 0.63 ± 0.16, 1.19 ± 0.28, and 14.01 ± 2.88, respectively; and when applying our method to non-MICCAI data, results were 3.21 ± 0.75, 0.06 ± 1.29, 0.45 ± 0.17, 0.98 ± 0.26, and 12.69 ± 3.89, respectively. These results demonstrate high performance of the method when applied to different CT datasets. CONCLUSIONS: BVs can be used to address the wide variability in liver shape and size, as BVs provide unique details for the structure of each studied liver. Constructing a boundary surface using HBVs and non-HBVs can separate liver from its neighboring organs of similar intensity. By fitting the histogram of the core region using a variational Bayesian Gaussian mixture model, LITs are segmented and measuring the volumetry of non-LIT- and LIT-parts becomes possible. Further examination of the proposed method on a large number of datasets is required for clinical applications, and development of the method for full automation may be possible and useful in the clinic.

Evaluation of optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI using MR fluoroscopic triggering and slow injection technique.

OBJECTIVE: The purpose of this article is to prospectively evaluate the optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI of hypervascular hepatocellular carcinoma (HCC) using MR fluoroscopic triggering and a slow-injection technique. SUBJECTS AND METHODS: Sixty-three patients (37 men and 26 women; age range, 33-92 years; mean age, 68.2 years) underwent gadoxetate disodium-enhanced MRI; there were 33 hypervascular HCCs (size range, 8-57 mm; mean size, 19.8 mm) in 19 patients. The time from the start of contrast agent injection to its arrival in the abdominal aorta (time to arrival) and the time from contrast agent arrival to peak enhancement (time to peak) were determined using MR fluoroscopy using IV slow injection at 1 mL/s of contrast material and a saline chaser. All patients underwent four-phase whole-liver imaging with a 3D keyhole gradient-echo sequence during a single breath-hold immediately after confirmation of aortic peak enhancement. Delays from peak aortic enhancement to k-space filling were 5-9, 10-14, 15-19, and 20-28 seconds, respectively, in the four phases. Time to arrival, time to peak, and HCC-to-liver contrast were evaluated. RESULTS: The time to arrival (range, 11-24 seconds; mean, 16.2 seconds) and the time to peak (range, 3-10 seconds; mean, 6.8 seconds) showed considerable variation among patients. HCC-to-liver contrast peaked at the first phase in 58% of cases, at the second phase in 42% of cases, and at the third and fourth phases in 0% of cases. Mean HCC-to-liver contrast in the first and second phases was significantly higher than that in the third and fourth phases (p<0.01). CONCLUSION: Optimal scan delays for imaging hypervascular HCCs with gadoxetate disodium-enhanced hepatic arterial phase MRI was 7-12 seconds after the peak aortic enhancement using a slow-injection protocol.

The value of chest tomosynthesis in locating a ground glass nodule (GGN) during endobronchial ultrasonography with a guide sheath: a case report.

A 74-year-old man was referred to our department for work-up of a pure ground glass nodule (GGN) on computed tomography (CT). He was suspected to have lung cancer by CT scan, but no lesion was visible on chest X-ray. Chest tomosynthesis was performed before bronchoscopy, showing a clear GGN. We could not detect a tumor signal on endobronchial ultrasonography so we relied on the chest tomosynthesis image as a guide during transbronchial biopsy. The diagnosis of adenocarcinoma was confirmed on histopathology. In this case, transbronchial biopsy under the guidance of chest tomosynthesis was useful for the diagnosis of GGN.

Intensity correction method customized for multi-animal abdominal MR imaging with 3T clinical scanner and multi-array coil.

PURPOSE: Simultaneous magnetic resonance (MR) imaging of multiple small animals in a single session increases throughput of preclinical imaging experiments. Such imaging using a 3-tesla clinical scanner with multi-array coil requires correction of intensity variation caused by the inhomogeneous sensitivity profile of the coil. We explored a method for correcting intensity that we customized for multi-animal MR imaging, especially abdominal imaging. METHOD: Our institutional committee for animal experimentation approved the protocol. We acquired high resolution T1-, T2-, and T2*-weighted images and low resolution proton density-weighted images (PDWIs) of 4 rat abdomens simultaneously using a 3T clinical scanner and custom-made multi-array coil. For comparison, we also acquired T1-, T2-, and T2*-weighted volume coil images in the same rats in 4 separate sessions. We used software created in-house to correct intensity variation. We applied thresholding to the PDWIs to produce binary images that displayed only a signal-producing area, calculated multi-array coil sensitivity maps by dividing low-pass filtered PDWIs by low-pass filtered binary images pixel by pixel, and divided uncorrected T1-, T2-, or T2*-weighted images by those maps to obtain intensity-corrected images. We compared tissue contrast among the liver, spinal canal, and muscle between intensity-corrected multi-array coil images and volume coil images. RESULTS: Our intensity correction method performed well for all pulse sequences studied and corrected variation in original multi-array coil images without deteriorating the throughput of animal experiments. Tissue contrasts were comparable between intensity-corrected multi-array coil images and volume coil images. CONCLUSION: Our intensity correction method customized for multi-animal abdominal MR imaging using a 3T clinical scanner and dedicated multi-array coil could facilitate image interpretation.

Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.

PURPOSE: To investigate the best standardized uptake value (SUV) index for differentiation of adrenal metastases from adrenocortical adenomas using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT). MATERIALS AND METHODS: A total of 129 patients (82 males and 47 females; mean age 65.4 years) with extra-adrenal primary malignancies who had known or suspected adrenal lesions underwent FDG PET/CT examinations for detection, staging, re-staging, or recurrence of tumor. Among these patients, 45 adrenal lesions (22 adenomas and 23 metastases) in 41 patients were evaluated. The maximum SUVs for adrenal lesions (adrenal SUVmax) and mean liver and spleen SUVs were recorded, and the ratio of the adrenal SUVmax to the mean liver SUV (adrenal-to-liver SUV ratio) and that of the adrenal SUVmax to the mean spleen SUV (adrenal-to-spleen SUV ratio) were obtained. Diagnostic performances for the adrenal SUVmax, adrenal-to-liver SUV ratio, and adrenal-to-spleen SUV ratio were compared. RESULTS: The mean adrenal SUVmax, adrenal-to-liver SUV ratio, and adrenal-to-spleen SUV ratio were higher for adrenal metastases (8.4 ± 3.8, 3.0 ± 1.3, and 4.0 ± 1.9, respectively) than for adrenocortical adenomas (2.9 ± 1.0, 0.9 ± 0.3, and 1.3 ± 0.3, respectively) (P < 0.001). The area under the curve was higher for the adrenal-to-liver SUV ratio (0.99) than for the adrenal SUVmax (0.96) and adrenal-to-spleen SUV ratio (0.98). In the differentiation of adrenocortical adenomas and adrenal metastases, an adrenal-to-liver SUV ratio cutoff value of 1.37 yielded a sensitivity of 96% and specificity of 100%. CONCLUSION: In FDG PET/CT analysis, the adrenal-to-liver SUV ratio had a greater ability to differentiate adrenocortical adenomas and adrenal metastases than did the adrenal SUVmax or adrenal-to-spleen SUV ratio.

Body size indices to determine iodine mass with contrast-enhanced multi-detector computed tomography of the upper abdomen: does body surface area outperform total body weight or lean body weight?

OBJECTIVE: To compare total body weight (TBW), lean body weight (LBW) and body surface area (BSA) for the adjustment of the iodine dose required for contrast-enhanced multi-detector computed tomography (MDCT) of the aorta and the liver. METHODS: One hundred and three patients undergoing MDCT of the abdomen were randomised into three groups: the TBW group receiving 0.6 g iodine/kg of TBW (n = 33), the LBW group receiving 0.75 g iodine/kg of LBW (n = 35) and the BSA group receiving 22 g iodine/m(2) (n = 35). ∆HU (increases in CT value) per gram of iodine (∆HU/g) and adjusted maximum hepatic enhancement (adjusted MHE; ∆HU/[g iodine/kg]) correlated with three groups using linear regressions. RESULTS: Correlation coefficients of ∆HU/g were 0.67 (TBW), 0.86 (LBW) and 0.85 (BSA) for the aorta, and 0.74 (TBW), 0.77 (LBW) and 0.84 (BSA) for the liver. Adjusted MHE was constant at 70.2 with LBW and at 2.69 with BSA, but correlated positively with TBW (r = 0.58, P < 0.001). CONCLUSION: Iodine load may need to be tailored by LBW or BSA in contrast enhanced MDCT of the abdomen. BSA is a simple and feasible index for the determination of iodine dose in individual patients. KEY POINTS: • Optimisation of enhancement is very important for high quality MDCT. • Iodine dose is best adjusted according to LBW or BSA. • BSA may be adopted because calculation is simple. • Iodine dose of 0.712 g/kg LBW/18.6 g/m (2) BSA gives 50 HU hepatic enhancement.

Delayed hepatic signal recovery on ferucarbotran-enhanced magnetic resonance images: an experimental study in rat livers with gadolinium chloride-induced Kupffer cell damage.

OBJECTIVE: Hepatic signal recovery, rather than reduction, in ferucarbotran-enhanced magnetic resonance imaging (MRI) is a potential diagnostic marker of liver damage. We investigated hepatic signal recovery in rats with gadolinium chloride (GdCl3)-induced Kupffer cell (KC) damage. MATERIALS AND METHODS: Twelve rats received 8 µmol iron/kg of ferucarbotran 1 day after 0-7.5 mg/kg GdCl3 injection (experiment A). Another 12 rats received ferucarbotran followed by GdCl3 injection 6 h later (experiment B). In each experiment, three rats without GdCl3 ("no injury group") served as control. Another six rats received GdCl3 alone without ferucarbotran. Hepatic signals were assessed on T 2 (*) -weighted images for up to 29 days. Iron deposits were histologically examined on day 29. RESULTS: Hepatic signal recovery was delayed in a GdCl3 dose-dependent manner in experiment A. Gadolinium chloride alone reduced hepatic signal 15 % during this experiment. Hepatic signal recovery was delayed only in rats that received 7.5 mg/kg GdCl3 in experiment B. Hepatic signals negatively correlated with iron deposits in KCs and hepatocytes. CONCLUSION: Hepatic signal recovery on ferucarbotran-enhanced MRI was delayed in the context of GdCl3-induced KC damage due to increased hepatic iron deposits. Hepatic signal recovery may be used as a clinical marker of KC damage in liver disorders, including radiation-induced hepatitis.

Detection and characterization of focal hepatic lesions with diffusion-weighted MR imaging: a pictorial review.

The purpose of this pictorial review is to discuss the usefulness and limitations of diffusion-weighted (DW) MR imaging of the liver, demonstrating DW images of a variety of focal hepatic diseases. We include hepatocellular carcinoma, borderline-lesions in cirrhosis, metastasis, cavernous hemangioma, cyst, focal nodular hyperplasia, hepatic adenoma, abscess, and hematoma. DW imaging is an important supplementary sequence of routine MR imaging protocols of the liver. Radiologists need to understand its usefulness and limitations in the detection and characterization of benign and malignant focal hepatic diseases.

Diffusion/perfusion MR imaging of the liver: practice, challenges, and future.

Diffusion-weighted (DWI) magnetic resonance (MR) imaging is useful in diagnosing various pathologic conditions in the liver, such as malignant tumors or hepatic fibrosis, and is now part of routine MR imaging protocols for the liver following the development of a parallel encoding technique that has markedly improved image quality. DWI is not very sensitive for detecting hepatocellular carcinomas (HCC) and is useless for characterizing border-line hepatocellular nodules in cirrhosis, but it complements gadolinium-enhanced MR imaging in detecting regional tumor recurrence or intrahepatic metastases of HCC following treatment. DWI is more useful for detecting hepatic metastasis, because histopathologic architecture of metastases does not resemble that of liver tissue and T(2) relaxation time of hepatic metasitasis is fairly longer than that of liver parenchyma. DWI is also useful for detecting moderate and advanced hepatic fibrosis. In cirrhosis, however, decreased blood flow in fibrotic liver is thought to lower apparent diffusion coefficient of the liver. For MR perfusion analysis, a dual-input one-compartment model is used to correlate various hepatic blood flow parameters that represent hepatic arterial/portal blood flow or fraction, mean transit time, and distribution volume with the severity of cirrhosis and portal hypertension. Conventional multisectional imaging and perfusion study can be combined using a 3-dimensional sequence with high temporal resolution, but spatial resolution is not sufficiently high to diagnose tiny hepatic lesions. The advent of liver-specific contrast agents, such as gadoxetic acid, may spur the development of a new analysis model that incorporates extracellular perfusion and hepatocyte function.

Enhancement of anatomical structures and detection of metastatic cervical lymph nodes: comparison of two different contrast material doses.

PURPOSE: To determine if a 20 % reduction in the contrast material dose is acceptable in the CT evaluation of patients with head and neck malignancy. MATERIALS AND METHODS: Sixty consecutive patients (mean age 67 years) with head and neck malignancy underwent contrast-enhanced CT according to two different protocols: protocol A (80 mL of contrast material administered at an injection rate of 1.5 mL/s) and protocol B (100 mL at 1.9 mL/s). The enhancement of anatomical structures and detectability of metastatic nodes were compared between the two protocols. Pathologic analysis of the surgical resection served as the reference standard. RESULTS: CT numbers of the anatomical structures were not significantly different between the two protocols. Mean sensitivity (64 and 77 % for protocols A and B, respectively), specificity (78 and 84 %), and accuracy (74 and 83 %) tended to be higher for protocol B than for A, but no significant difference was found. CONCLUSION: Reducing the contrast material dose by 20 % did not significantly impair the enhancement of anatomical structures or the detection of metastatic cervical lymph nodes. Radiologists should therefore consider reducing the contrast material dose used in head and neck CT.

Detection of focal hepatic lesions with 3-T MRI: comparison of two-dimensional and three-dimensional T2-weighted sequences.

PURPOSE: To evaluate whether incorporation of a 3D turbo spin-echo sequence during T2-weighted MR imaging improves the detection of focal hepatic lesions by 3T MR imaging. MATERIALS AND METHODS: Seventy-nine consecutive patients including 67 patients with 62 malignant and 71 benign lesions and 12 patients having no hepatic lesion underwent respiratory-triggered fat-suppressed axial T2-weighted turbo spin-echo imaging using two-dimensional (2D-TSE) and 3D (3D-TSE) sequences. Coronal multiplanar reformatted images (MPR-3D-TSE) were generated from 3D-TSE images. Breath-hold fat-suppressed 2D axial T2-weighted half-Fourier turbo spin-echo (HF-2D-TSE) images were combined for reading. Two independent radiologists reviewed three imaging sets, (1) 2D-TSE and HF-2D-TSE, (2) 3D-TSE and HF-2D-TSE, and (3) 3D-TSE, HF-2D-TSE and MPR-3D-TSE, for detection of malignant and benign lesions. Lesion-to-liver contrast ratio (CR) and the conspicuity of anatomical boundaries were assessed. RESULTS: For benign lesions, lesion-to-liver CRs with 3D-TSE (2.77 ± 1.91, p = .0002) and MPR-3D-TSE (2.47 ± 1.42, p = .012) were higher than with 2D-TSE (2.13 ± 1.80). Sensitivity for lesions of ≤ 10-mm was higher with 3D-TSE (86 %, p = .0039) and MPR-3D-TSE (84 %, p = .0078) than with 2D-TSE (72 %). However, the edge of left lateral lobe was less conspicuous with 3D-TSE (p < .0001) and MPR-3D-TSE (p = .0003) than with 2D-TSE because of susceptibility artifacts. CONCLUSION: Incorporation of 3D T2-weighted sequence may incrementally improve the detection of focal hepatic lesions.